Kynamro market seen growing on rare-disease demand and cardiovascular risk

The Business Research Company says the global Kynamro market is set for long-term growth through 2035, driven by rising cardiovascular disease, more hypercholesterolemia cases and broader use of personalized therapies. North America led the market in 2025, while Europe is expected to grow fastest over the forecast period.

Why it matters: - Kynamro sits in a niche but growing treatment area: rare genetic lipid disorders and difficult-to-control high cholesterol. - The market outlook matters because demand is tied to broader cardiovascular risk, which affects far more patients than HoFH alone. - The report points to longer-term opportunity for specialty lipid drugs as genetic screening and personalized care expand.

What happened: - The Business Research Company released its Kynamro Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Kynamro market has been supported by better understanding of genetic lipid disorders, regulatory approvals for antisense therapies and unmet need in homozygous familial hypercholesterolemia, or HoFH. - The report projects additional growth from next-generation lipid therapies, competition from novel biologic drugs, broader genetic screening and wider access to specialty medicines.

The details: - Kynamro is designed to treat HoFH, a rare genetic disorder that causes dangerously high cholesterol. - The drug works by inhibiting production of apolipoprotein B-100, a protein needed to form LDL cholesterol. - Kynamro is used with other lipid-lowering therapies for patients who have not achieved enough control with standard treatment. - The report flags several trends: more use of targeted lipid-lowering agents, broader rare-disease treatment protocols, growth in injectable cholesterol therapies, stronger focus on adherence and more combination lipid regimens. - The company also says the global market will be shaped by personalized cardiovascular care and wider access to specialty medications. - A sample report is available here. - The full report is available here.

Between the lines: - Rising cardiovascular disease is the main growth driver cited in the release. - The report links that trend to aging populations, poor diet, sedentary lifestyles, smoking, alcohol use, obesity and diabetes. - The release cites British Heart Foundation projections from September 2025 showing the number of people living with cardiovascular disease in the UK could rise by 1 million by 2030 and double by 2040. - Personalized medicine is another catalyst, with Kynamro positioned as a therapy for patients whose LDL cholesterol is driven by genetics. - The release cites Personalized Medicine Coalition data from February 2024 showing the FDA approved 16 personalized treatments for rare diseases in 2023, up from six in 2022. - Growing hypercholesterolemia rates also support demand for advanced cholesterol-lowering drugs. - The release cites a PubMed study from July 2025 showing use of therapies such as PCSK9 inhibitors rose from 33% in the first half of 2023 to 40% in the first half of 2024.

What’s next: - North America held the largest share of the global Kynamro market in 2025. - Europe is expected to be the fastest-growing region during the forecast period. - The report also tracks opportunities in Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and future trend analysis.

The bottom line: - Kynamro’s growth story is less about mass-market volume and more about a widening clinical need for targeted, personalized treatment in hard-to-manage cholesterol disorders.